Pneumocystis carinii pneumonia: therapy and prophylaxis.
Kovacs
J A
JA
Critical Care Medicine Department, National Institutes of Health, Bethesda, Maryland 20892.
Masur
H
H
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D010419:Pentamidine / Q000008:administration & dosage / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D011739:Pyrimethamine / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D012008:Recurrence; D013411:Sulfadiazine / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014295:Trimethoprim / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D016597:Trimetrexate
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D011799:Quinazolines; D013411:Sulfadiazine; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D014295:Trimethoprim; D013420:Sulfamethoxazole; D016597:Trimetrexate; D011739:Pyrimethamine